文献速递白血病

儿童及青年急性淋巴细胞白血病的治愈时间独立于早期危险因素:UKALL2003试验长期随访

Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
PubMed 文献 · J Clin Oncol · 2022-06-17

UKALL2003随机试验基于微小残留病(MRD)分层调整治疗强度,分析3113例患者(1054例随机分组:521例MRD低危、533例MRD高危)的10年随机结局及治愈时间。中位随访10.98年,低危组一次延迟强化与两次延迟强化无事件生存率无显著差异,高危组标准治疗与强化治疗无事件生存率无显著差异,但细胞遗传学高危患者强化治疗复发风险更低。所有亚组复发风险在诊断后约6年趋于一致,治愈时间与危险组无关。

要点

  • 低危组一次与两次延迟强化10年无事件生存率无显著差异,低危患者可安全降低治疗强度。
  • 高危组标准与强化治疗10年无事件生存率无显著差异,但细胞遗传学高危患者强化治疗复发风险更低。
  • 尽管初始复发风险因性别、年龄、MRD和遗传学而异,所有亚组复发风险在诊断后约6年趋于一致。

核心结论

  • UKALL2003试验长期结局证实低危患者可安全降低治疗强度,而强化治疗使细胞遗传学高危患者获益。
  • 无论预后如何,各危险组的治愈时间相似,这有助于回答患者及家庭关于「何时治愈」的问题。

研究设计与样本

  • UKALL2003是一项随机试验,基于微小残留病(MRD)分层调整儿童及青年急性淋巴细胞白血病的治疗强度(ClinicalTrials.gov标识:NCT00222612)。
  • 共分析3113例患者,其中1054例接受随机分组:521例MRD低危、533例MRD高危。
  • 治愈时间定义为复发概率<1%的时间点;中位随访10.98年(四分位距9.19-13.02),生存率报告为10年数值。

主要发现

  • 低危组:一次延迟强化10年无事件生存率91.7%(95%CI 87.4-94.6)vs 两次延迟强化93.7%(95%CI 89.9-96.1),校正风险比0.73(95%CI 0.38-1.40;P=0.3)。
  • 高危组:标准治疗10年无事件生存率82.1%(95%CI 76.9-86.2)vs 强化治疗87.1%(95%CI 82.4-90.6),校正风险比0.68(95%CI 0.44-1.06;P=0.09)。
  • 细胞遗传学高危患者:强化治疗复发风险22.1%(95%CI 15.1-31.6)vs 标准治疗52.4%(95%CI 28.9-80.1;P=0.016)。
  • 初始复发风险因性别、年龄、MRD和遗传学显著不同,但所有亚组复发风险在诊断后约6年快速趋于一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of the randomized trial, UKALL2003, was to adjust treatment intensity on the basis of minimal residual disease (MRD) stratification for children and young adults with acute lymphoblastic leukemia. We analyzed the 10-year randomized outcomes and the time for patients to be considered cured (ClinicalTrials.gov identifier: NCT00222612). METHODS: A total of 3,113 patients were analyzed including 1,054 patients who underwent random assignment (521 MRD low-risk and 533 MRD high-risk patients). Time to cure was defined as the point at which the chance of relapse was < 1%. The median follow-up time was 10.98 (interquartile range, 9.19-13.02) years, and survival rates are quoted at 10 years. RESULTS: In the low-risk group, the event-free survival was 91.7% (95% CI, 87.4 to 94.6) with one course of delayed intensification versus 93.7% (95% CI, 89.9 to 96.1) with two delayed intensifications (adjusted hazard ratio, 0.73; 95% CI, 0.38 to 1.40; P = .3). In the high-risk group, the event-free survival was 82.1% (95% CI, 76.9 to 86.2) with standard therapy versus 87.1% (95% CI, 82.4 to 90.6) with augmented therapy (adjusted hazard ratio, 0.68; 95% CI, 0.44 to 1.06; P = .09). Cytogenetic high-risk patients treated on augmented therapy had a lower relapse risk (22.1%; 95% CI, 15.1 to 31.6) versus standard therapy (52.4%; 95% CI, 28.9 to 80.1; P = .016). The initial risk of relapse differed significantly by sex, age, MRD, and genetics, but the risk of relapse for all subgroups quickly coalesced at around 6 years after diagnosis. CONCLUSION: Long-term outcomes of the UKALL2003 trial confirm that low-risk patients can safely de-escalate therapy, while intensified therapy benefits patients with high-risk cytogenetics. Regardless of prognosis, the time to cure is similar across risk groups. This will facilitate communication to patients and families who pose the question "When am I/is my child cured?"

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Moorman AV, Antony G, Wade R, et al. Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial. J Clin Oncol. 2022. PMID: 35714315. doi:10.1200/JCO.22.00245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。